177 related articles for article (PubMed ID: 19618079)
1. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.
Brito Mde F; Ximenes RA; Gallo ME; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():67-72. PubMed ID: 19618079
[TBL] [Abstract][Full Text] [Related]
2.
Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
Front Immunol; 2018; 9():915. PubMed ID: 29867930
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.
Richardus RA; van der Zwet K; van Hooij A; Wilson L; Oskam L; Faber R; van den Eeden SJF; Pahan D; Alam K; Richardus JH; Geluk A
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006083. PubMed ID: 29228004
[TBL] [Abstract][Full Text] [Related]
4. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
[TBL] [Abstract][Full Text] [Related]
5. Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients.
Zenha EM; Ferreira MA; Foss NT
Braz J Med Biol Res; 2009 Oct; 42(10):968-72. PubMed ID: 19784481
[TBL] [Abstract][Full Text] [Related]
6. Leprosy serology using PGL-I: a systematic review.
Moura RS; Calado KL; Oliveira ML; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():11-8. PubMed ID: 19618069
[TBL] [Abstract][Full Text] [Related]
7. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Hungria EM; Oliveira RM; Penna GO; Aderaldo LC; Pontes MA; Cruz R; Gonçalves HS; Penna ML; Kerr LR; Stefani MM; Bührer-Sékula S
Infect Dis Poverty; 2016 Dec; 5(1):110. PubMed ID: 27919284
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for ML Flow seropositivity in leprosy patients.
Grossi MA; Leboeuf MA; Andrade AR; Bührer-Sékula S; Antunes CM
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():39-44. PubMed ID: 19618074
[TBL] [Abstract][Full Text] [Related]
9. Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.
Mizoguti Dde F; Hungria EM; Freitas AA; Oliveira RM; Cardoso LP; Costa MB; Sousa AL; Duthie MS; Stefani MM
Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):914-20. PubMed ID: 26560982
[TBL] [Abstract][Full Text] [Related]
10. Can anti-PGL-1 and anti-NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?
Devides AC; Rosa PS; de Faria Fernandes Belone A; Coelho NMB; Ura S; Silva EA
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):260-265. PubMed ID: 29669693
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
12. The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients.
Roche PW; Britton WJ; Neupane KD; Failbus SS; Cho SN; Theuvenet WJ
Am J Trop Med Hyg; 1991 Jun; 44(6):702-8. PubMed ID: 1858971
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium leprae particle agglutination in diagnosis and monitoring of treatment of leprosy.
Kampirapap K
J Med Assoc Thai; 1999 Oct; 82(10):1020-4. PubMed ID: 10561966
[TBL] [Abstract][Full Text] [Related]
15. Association between anti-pGL-I IgM and clinical and demographic parameters in leprosy.
Schuring RP; Moet FJ; Pahan D; Richardus JH; Oskam L
Lepr Rev; 2006 Dec; 77(4):343-55. PubMed ID: 17343221
[TBL] [Abstract][Full Text] [Related]
16. Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.
Barreto JA; Nogueira ME; Diorio SM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():45-7. PubMed ID: 19618075
[TBL] [Abstract][Full Text] [Related]
17. Active search for leprosy cases in Midwestern Brazil: a serological evaluation of asymptomatic household contacts before and after prophylaxis with bacillus Calmette-Guérin.
Limeira OM; Gomes CM; Morais OO; Cesetti MV; Alvarez RR
Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740009
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the effects of preventive therapy in the Federated States of Micronesia.
Cho SN; Walsh GP; Brennan PJ
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S19-22. PubMed ID: 10700932
[No Abstract] [Full Text] [Related]
19. Antibody response to phenolic glycolipid I and Mycobacterium w antigens and its relation to bacterial load in M. leprae-infected mice and leprosy patients.
Moudgil KD; Gupta SK; Naraynan PR; Srivastava LM; Mishra RS; Talwar GP
Clin Exp Immunol; 1989 Nov; 78(2):214-8. PubMed ID: 12412751
[TBL] [Abstract][Full Text] [Related]
20. Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.
Düppre NC; Camacho LA; Sales AM; Illarramendi X; Nery JA; Sampaio EP; Sarno EN; Bührer-Sékula S
PLoS Negl Trop Dis; 2012; 6(6):e1711. PubMed ID: 22724040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
